Publications by authors named "Paul Pollack"

Claim this Profile
E
Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial.
Fernando Magro, Marijana Protic, Gert De Hertogh, Lai Shan Chan, Paul Pollack

Clin Gastroenterol Hepatol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.
Bruce E Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, Peter D R Higgins, Monika Fischer, Paul F Pollack

Gastroenterology· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.
Katherine Li, Joshua R Friedman, Daphne Chan, Paul Pollack, Feifei Yang

Gastroenterology· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Paul Rutgeerts, Christopher Gasink, Daphne Chan, Yinghua Lang, Paul Pollack

Gastroenterology· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Pancrelipase/Pancreatin in Patients With Exocrine Pancreatic Insufficiency and a Medical History of Diabetes Mellitus.
David C Whitcomb, Amit Bodhani, Katrin Beckmann, Suntje Sander-Struckmeier, Shufang Liu, Paul F Pollack

Pancreas· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children.
Saleh Al-Alaiyan, Paul Pollack, Gerard F Notario

Drugs Context· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Milk protein-based infant formula containing rice starch and low lactose reduces common regurgitation in healthy term infants: a randomized, blinded, and prospective trial.
John B Lasekan, Hawley K Linke, Jeffery S Oliver, Jane D Carver, Mark M Blatter, Paul F Pollack

J Am Coll Nutr· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.
Mark T Osterman, William J Sandborn, Jean-Frederic Colombel, Anne M Robinson, Winnie Lau, Paul F Pollack

Gastroenterology· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab induces deep remission in patients with Crohn's disease.
Jean-Frédéric Colombel, Paul J Rutgeerts, William J Sandborn, Mei Yang, Anne Camez, Paul F Pollack

Clin Gastroenterol Hepatol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective analysis to investigate the effect of concomitant use of gastric acid-suppressing drugs on the efficacy and safety of pancrelipase/pancreatin (CREON®) in patients with pancreatic exocrine insufficiency.
Suntje Sander-Struckmeier, Katrin Beckmann, Gwendolyn Janssen-van Solingen, Paul Pollack

Pancreas· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants.
Walter Reinisch, William J Sandborn, Remo Panaccione, Bidan Huang, Paul F Pollack

Inflamm Bowel Dis· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum adalimumab concentration and clinical remission in patients with Crohn's disease.
Yi-Lin Chiu, David T Rubin, Severine Vermeire, Edouard Louis, Anne M Robinson, Paul F Pollack

Inflamm Bowel Dis· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial.
Edouard Louis, Robert Löfberg, Walter Reinisch, Anne Camez, Mei Yang, Paul F Pollack

J Crohns Colitis· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial.
David T Rubin, Parvez Mulani, Jingdong Chao, Paul F Pollack, Arielle G Bensimon

Inflamm Bowel Dis· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
Paul Rutgeerts, Gert Van Assche, William J Sandborn, Douglas C Wolf, Karel Geboes, Paul F Pollack

Gastroenterology· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE.
Robert Löfberg, Edouard V Louis, Walter Reinisch, Anne M Robinson, Martina Kron, Paul F Pollack

Inflamm Bowel Dis· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When meta-analysis misleads.
Mei Yang, Anne M Robinson, Paul F Pollack

Am J Gastroenterol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics.
William J Sandborn, Jean-Frédéric Colombel, Stefan Schreiber, Scott E Plevy, Paul F Pollack

Inflamm Bowel Dis· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective.
Eric Qiong Wu, Parvez M Mulani, Andrew Peng Yu, Jackson Tang, Paul F Pollack

Value Health· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Jean-Frédéric Colombel, William J Sandborn, Paul Rutgeerts, Michael A Kamm, Andrew P Yu, Paul F Pollack

Am J Gastroenterol· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
Edward V Loftus, Brian G Feagan, Jean-Frédéric Colombel, David T Rubin, Eric Q Wu, Paul F Pollack

Am J Gastroenterol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
William J Sandborn, Paul Rutgeerts, Robert Enns, Stephen B Hanauer, Jean-Frédéric Colombel, Paul F Pollack

Ann Intern Med· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Jean-Frédéric Colombel, William J Sandborn, Paul Rutgeerts, Robert Enns, Stephen B Hanauer, Paul F Pollack

Gastroenterology· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
Stephen B Hanauer, William J Sandborn, Paul Rutgeerts, Richard N Fedorak, Milan Lukas, Paul Pollack

Gastroenterology· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of a premixed, rice-based oral rehydration solution.
Irene Maulen-Radovan, Pedro Gutierrez-Castrellón, Mohamed Hashem, Michael Neylan, Geraldine Baggs, Paul F Pollack

J Pediatr Gastroenterol Nutr· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis